Merkel Cell Carcinoma Disease Treatment Market - Forecasts from 2018 to 2023

Merkel Cell Carcinoma Disease Treatment Market - Forecasts from 2018 to 2023

The merkel cell carcinoma disease treatment market is projected to grow at a CAGR of XX.XX% to reach US$XX.XXX billion by 2023, from US$XX.XXX billion in 2017. The presence of the Merkel cells can be found in the touch-sensitive area of the epidermis, which is also known as the outermost layer of the skin. Merkel cell carcinoma is considered to be an aggressive form of skin cancer which metastasizes very fast to other areas of the body. There are several drugs are in the pipeline for the development of the effective disease treatment. However, the exact cause of the disease is unknown, but excessive sunlight exposure and a weakened immune system may aggravate the risk of cancer. Rising disease incidence, rising healthcare expenditure, and growing research and development investments are driving the growth of the Merkel cell carcinoma disease treatment market in the forecast period. Europe and North America are expected to hold a significant market share due to the growing incidences of this disease in the United States, France, Germany, and Sweden among other regions. Additionally, China and Australia from the APAC region also have growing incidences of Merkel cell carcinoma where the market may thrive owing to the need for disease treatment in these regions.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the merkel cell carcinoma disease treatment value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the merkel cell carcinoma disease treatment market.

Major industry players profiled as part of the report are Merck KGaA, Darmstadt, Germany, Pfizer Inc., Millennium Pharmaceuticals Inc., APCure SAS, and Bristol-Myers Squibb Company among others.

Segmentation

The merkel cell carcinoma disease treatment market has been analyzed through following segments:

By Treatment

Immunotherapy

Surgical Excision

Radiation Therapy

Others

 

By Disease Stage

Local (Skin only)

Nodal (includes lymph nodes)

Metastatic (spreads elsewhere in the body)

 

By Geography

North America

USA

Canada

Mexico

Others

 

South America

Brazil

Argentina

Others

 

Europe

Germany

France

United Kingdom

Spain

Others

 

Middle East and Africa

Saudi Arabia

Israel

Others

 

Asia Pacific

China

Japan

South Korea

India

Others

 

Target audience

Manufacturers

Suppliers

Distributors

Service Providers

Government Agencies

Research Organizations

Consultants


Key insights offered

What will be the merkel cell carcinoma disease treatment market size from 2017 to 2023?

How are the major drivers and restraints affecting the merkel cell carcinoma disease treatment market growth and the opportunities which exist for key vendors?

Which segment and region will drive or lead the market growth and why?

A comprehensive analysis of competitive landscape and key market participants’ behaviour

Key strategies being adopted by vendors, with in-depth analysis along with their impact on competition and market growth.

1. INTRODUCTION
2. RESEARCH METHODOLOGY  
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Prevalence
4.5.1. By age group
4.5.2. By gender
4.5.3. By region
4.6. Product Pipeline
4.7. Innovations
5. MERKEL CELL CARCINOMA DISEASE TREATMENT  MARKET BY TREATMENT
5.1. Immunotherapy
5.2. Surgical Excision
5.3. Radiation Therapy
5.4. Others
6. MERKEL CELL CARCINOMA DISEASE TREATMENT  MARKET BY DISEASE STAGE
6.1. Local (Skin only)
6.2. Nodal (includes lymph nodes)
6.3. Metastatic (spreads elsewhere in the body)
7. MERKEL CELL CARCINOMA DISEASE TREATMENT  MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentia
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1.  Market Share of Key Players
8.2.  Recent Investment and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Merck KGaA, Darmstadt, Germany
9.1.1. Overview
9.1.2. Products and Services
9.1.3. Financials
9.1.4. SWOT Analysis
9.2. Pfizer Inc.
9.2.1. Overview
9.2.2. Products and Services
9.2.3. Financials
9.2.4. SWOT Analysis
9.3.  Millennium Pharmaceuticals Inc.
9.3.1. Overview
9.3.2. Products and Services
9.3.3. Financials
9.3.4. SWOT Analysis
9.4. APCure SAS
9.4.1. Overview
9.4.2. Products and Services
9.4.3. Financials
9.4.4. SWOT Analysis
9.5.  Bristol-Myers Squibb Company
9.5.1. Overview
9.5.2. Products and Services
9.5.3. Financials
9.5.4. SWOT Analysis
9.6. Checkpoint Therapeutics, Inc.
9.6.1. Overview
9.6.2. Products and Services
9.6.3. Financials
9.6.4. SWOT Analysis
9.7. Immune Design
9.7.1. Overview
9.7.2. Products and Services
9.7.3. Financials
9.7.4. SWOT Analysis
9.8. Nektar Therapeutics
9.8.1. Overview
9.8.2. Products and Services
9.8.3. Financials
9.8.4. SWOT Analysis
9.9. Philogen S.p.A.
9.9.1. Overview
9.9.2. Products and Services
9.9.3. Financials
9.9.4. SWOT Analysis
LIST OF FIGURES
LIST OF TABLES
DISCLAIMER 

Merck KGaA, Darmstadt, Germany

Pfizer Inc.

Millennium Pharmaceuticals Inc.

APCure SAS

Bristol-Myers Squibb Company

Checkpoint Therapeutics, Inc.

Immune Design

Nektar Therapeutics

Philogen S.p.A.

  • SKU:
  • Publishing Date: 2019-01-09
  • Product Code: 1
  • Availability: In Stock
  • $3,950.00
  • Ex Tax: $3,950.00

Available Options